[go: up one dir, main page]

JO3182B1 - مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 - Google Patents

مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2

Info

Publication number
JO3182B1
JO3182B1 JOP/2010/0227A JOP20100227A JO3182B1 JO 3182 B1 JO3182 B1 JO 3182B1 JO P20100227 A JOP20100227 A JO P20100227A JO 3182 B1 JO3182 B1 JO 3182B1
Authority
JO
Jordan
Prior art keywords
antibodies
ang
generation
human
bind
Prior art date
Application number
JOP/2010/0227A
Other languages
English (en)
Inventor
Thurston Gavin
Daly Christopher
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3182(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3182B1 publication Critical patent/JO3182B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير أجسام مضادة ترتبط بأنجيوبيوتين-2(Ang-2) وطرق لاستخدامها . وطبقا لنماذج معينة من الاختراع, تكون الأجسام المضادة عبارة عن أجسام مضادة بشرية كاملة ترتبط بAng-2 البشري . وتكون الأجسام المضادة للأختراع مفيدة, من بين أشياء أخرى, لمعالجة أمراض واضطرابات مرتبطة بواحد أو أكثر من أنشطة Ang-2 بما في ذلك تكوين الأوعية.
JOP/2010/0227A 2009-07-29 2010-07-01 مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 JO3182B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22941809P 2009-07-29 2009-07-29
US29519410P 2010-01-15 2010-01-15

Publications (1)

Publication Number Publication Date
JO3182B1 true JO3182B1 (ar) 2018-03-08

Family

ID=42937802

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0227A JO3182B1 (ar) 2009-07-29 2010-07-01 مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2

Country Status (41)

Country Link
US (4) US8987420B2 (ar)
EP (1) EP2459592B1 (ar)
JP (1) JP5701876B2 (ar)
KR (1) KR101781786B1 (ar)
CN (2) CN104258390B (ar)
AR (1) AR077333A1 (ar)
AU (1) AU2010276544B2 (ar)
BR (1) BR112012001984B8 (ar)
CA (1) CA2769334C (ar)
CL (1) CL2012000229A1 (ar)
CO (1) CO6491118A2 (ar)
CR (1) CR20120086A (ar)
CY (1) CY1117695T1 (ar)
DK (1) DK2459592T3 (ar)
EC (1) ECSP12011694A (ar)
ES (1) ES2582405T3 (ar)
HK (2) HK1166806A1 (ar)
HR (1) HRP20161043T1 (ar)
HU (1) HUE030508T2 (ar)
IL (1) IL217680A (ar)
JO (1) JO3182B1 (ar)
MA (1) MA33534B1 (ar)
ME (1) ME02484B (ar)
MX (1) MX2012001094A (ar)
MY (1) MY156816A (ar)
NI (1) NI201200014A (ar)
NZ (1) NZ598202A (ar)
PE (1) PE20121129A1 (ar)
PH (1) PH12012500171A1 (ar)
PL (1) PL2459592T3 (ar)
PT (1) PT2459592T (ar)
RS (1) RS55054B1 (ar)
RU (1) RU2545399C2 (ar)
SG (1) SG178114A1 (ar)
SI (1) SI2459592T1 (ar)
SM (1) SMT201600251B (ar)
TN (1) TN2012000040A1 (ar)
TW (1) TWI527591B (ar)
UY (1) UY32812A (ar)
WO (1) WO2011014469A1 (ar)
ZA (1) ZA201200658B (ar)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
RS52036B (en) * 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
EP2237797A4 (en) 2008-01-03 2012-11-07 Scripps Research Inst ANTIBODY TARGETING BY MODULAR DETECTION DOMAIN
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CN105340834B (zh) 2009-07-08 2018-11-06 科马布有限公司 动物模型及治疗分子
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
WO2012137993A1 (en) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2013028442A1 (en) 2011-08-19 2013-02-28 Regeneron Pharmaceuticals, Inc Anti-tie2 antibodies uses thereof
JP5813880B2 (ja) 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
NZ623086A (en) 2011-09-30 2016-08-26 Dana Farber Cancer Inst Inc Therapeutic peptides
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CN104169299B (zh) * 2012-01-23 2018-06-05 瑞泽恩制药公司 含抗Ang-2 抗体的稳定化制剂
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
MX350248B (es) * 2012-03-30 2017-08-31 Boehringer Ingelheim Int Moleculas de union a ang2.
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
TWI641619B (zh) * 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
WO2014034735A1 (ja) 2012-08-31 2014-03-06 国立大学法人 大阪大学 Ｖｅｇｆ及び／又はアンギオポエチン－２の特異的エピトープを含むｄｎａワクチン
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MX2015003895A (es) * 2012-09-28 2015-07-17 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf-r.
EA201500371A1 (ru) * 2012-09-28 2015-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
KR20150084007A (ko) 2012-11-13 2015-07-21 리제너론 파아마슈티컬스, 인크. 항-프로키네티신 수용체 (ｐｒｏｋｒ) 항체 및 이의 용도
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
MX2015011075A (es) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Peptidos terapeuticos.
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
PT3003038T (pt) 2013-06-07 2019-11-19 Scripps Research Inst Derivados 2h-1,2,3-triazólicos como inibidores de fibrose
EP2832746B1 (en) 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-Ang2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
KR102338453B1 (ko) 2013-10-18 2021-12-13 리제너론 파아마슈티컬스, 인크. Ｖｅｇｆ 길항제와 항-ｃｔｌａ-4 항체의 조합물을 포함하는 조성물 및 방법
MX2016005446A (es) * 2013-11-01 2017-01-05 Regeneron Pharma Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
NZ724229A (en) 2014-03-11 2023-06-30 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
CA3124243A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
JP2017514854A (ja) * 2014-05-07 2017-06-08 メディミューン，エルエルシー 抗ａｎｇ２抗体を用いる方法
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
KR102349370B1 (ko) 2014-05-26 2022-01-10 삼성전자주식회사 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도
AU2015331602A1 (en) * 2014-10-17 2017-04-27 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
WO2016073157A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
JP6706023B2 (ja) 2014-12-10 2020-06-03 ザ・スクリップス・リサーチ・インスティテュート 線維症の小分子阻害剤
WO2016115218A1 (en) * 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions
CA2973964A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
MX2017012380A (es) 2015-03-27 2018-04-11 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
WO2017049038A2 (en) * 2015-09-16 2017-03-23 Ablexis, Llc Anti-cd115 antibodies
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
KR102714544B1 (ko) 2015-12-16 2024-10-10 리제너론 파마슈티칼스 인코포레이티드 단백질 극미립자를 제조하기 위한 조성물 및 방법
KR20180099892A (ko) 2016-01-25 2018-09-05 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
EP3411408B1 (en) 2016-02-02 2021-12-08 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
CA3031542A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
EP3515487B1 (en) 2016-09-23 2023-07-19 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
WO2018089508A2 (en) * 2016-11-08 2018-05-17 Ablexis, Llc Anti-cd47 antibodies
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EA201900312A1 (ru) 2016-11-29 2019-12-30 Регенерон Фармасьютикалз, Инк. Способы лечения пролактин-рецептор положительного рака молочной железы
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
JP7161494B2 (ja) 2017-05-06 2022-10-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法
US11434303B2 (en) 2017-06-28 2022-09-06 Bluefin Biomedicine, Inc. Anti-LY6H antibodies and antibody drug conjugates
CN110662771B (zh) * 2018-02-01 2023-07-28 南京驯鹿生物技术股份有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
EP3774866A1 (en) 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
EP3788075A1 (en) 2018-04-30 2021-03-10 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
CN112399975B (zh) 2018-06-07 2024-05-17 基础科学研究院 与Tie2结合的抗体及其用途
WO2019235856A1 (ko) 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
SG11202108525VA (en) 2019-02-21 2021-09-29 Regeneron Pharma Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
SG11202108832XA (en) * 2019-02-25 2021-09-29 Pharmabcine Inc Anti-ang2 antibody and use thereof
US20230174627A1 (en) * 2019-05-14 2023-06-08 Jeffrey W. FROUDE Antibodies to sudan and ebola virus
CA3141628A1 (en) * 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
CN113993547B (zh) 2019-06-21 2024-04-26 瑞泽恩制药公司 结合muc16和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
WO2020257681A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US20230141511A1 (en) 2019-12-20 2023-05-11 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
EP4110472A1 (en) 2020-02-28 2023-01-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
CN115244084A (zh) 2020-03-06 2022-10-25 瑞泽恩制药公司 抗gitr抗体及其用途
CN115916224A (zh) * 2020-04-24 2023-04-04 纪念斯隆-凯特琳癌症中心 靶向cd19的嵌合抗原受体及其用途
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
US20220072141A1 (en) 2020-07-13 2022-03-10 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
JP2023538526A (ja) * 2020-08-06 2023-09-08 ステレクシス セラピューティクス，エルエルシー Ｉｌ－８抗体及びその使用方法
JP2023536499A (ja) * 2020-08-07 2023-08-25 ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド ヒトアンジオポエチン－２に対する抗体及びその使用
IL301254A (en) 2020-09-11 2023-05-01 Janssen Biotech Inc Methods and compositions for modulating beta chain mediated immunity
WO2022056199A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022087243A1 (en) 2020-10-22 2022-04-28 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
KR20230107261A (ko) 2020-11-10 2023-07-14 리제너론 파마슈티칼스 인코포레이티드 셀레늄 항체 접합물
CN116964088A (zh) 2021-01-25 2023-10-27 里珍纳龙药品有限公司 用于治疗肺动脉高压（pah）的抗pdgf-b抗体和使用方法
AU2022298653A1 (en) 2021-06-22 2023-10-12 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
CN116178540A (zh) * 2021-11-26 2023-05-30 三优生物医药(上海)有限公司 抗ang2抗体及其用途
CA3241734A1 (en) 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
TWI833641B (zh) 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
IL317392A (en) 2022-06-07 2025-02-01 Regeneron Pharma Multispecific molecules for modulating T-cell activity and their uses
WO2024118785A2 (en) 2022-11-30 2024-06-06 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
CN116003591B (zh) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2抗体及其应用
WO2024138000A1 (en) 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
CN116789813B (zh) * 2023-06-27 2024-04-26 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
SG156668A1 (en) * 2004-10-19 2009-11-26 Amgen Inc Angiopoietin-2 specific binding agents
RS52036B (en) * 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
CA2598833A1 (en) 2005-03-03 2006-09-08 Curt W. Bradshaw Anti-angiogenic compounds
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
BRPI0619853A2 (pt) 2005-12-15 2016-08-23 Astrazeneca Ab combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
MX2011011925A (es) * 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
HK1166806A1 (zh) 2012-11-09
ZA201200658B (en) 2012-10-31
HRP20161043T1 (hr) 2016-10-21
BR112012001984B1 (pt) 2020-10-27
KR101781786B1 (ko) 2017-09-26
TN2012000040A1 (en) 2013-09-19
MX2012001094A (es) 2012-03-14
MY156816A (en) 2016-03-31
JP2013500970A (ja) 2013-01-10
DK2459592T3 (en) 2016-08-29
CY1117695T1 (el) 2017-05-17
US20210101969A1 (en) 2021-04-08
TWI527591B (zh) 2016-04-01
CN102549015A (zh) 2012-07-04
PH12012500171A1 (en) 2016-03-04
CN104258390B (zh) 2017-09-08
PE20121129A1 (es) 2012-09-04
NZ598202A (en) 2013-12-20
ECSP12011694A (es) 2012-04-30
HK1205470A1 (en) 2015-12-18
US10875911B2 (en) 2020-12-29
WO2011014469A1 (en) 2011-02-03
CN102549015B (zh) 2014-10-15
EP2459592B1 (en) 2016-05-18
HUE030508T2 (en) 2017-05-29
NI201200014A (es) 2012-05-29
EP2459592A1 (en) 2012-06-06
RU2012107286A (ru) 2013-09-10
SG178114A1 (en) 2012-03-29
MA33534B1 (ar) 2012-08-01
AU2010276544A1 (en) 2012-03-01
US20180186869A1 (en) 2018-07-05
SMT201600251B (it) 2016-08-31
JP5701876B2 (ja) 2015-04-15
US20110027286A1 (en) 2011-02-03
CL2012000229A1 (es) 2012-10-05
UY32812A (es) 2011-04-29
BR112012001984B8 (pt) 2021-05-25
PL2459592T3 (pl) 2016-11-30
SI2459592T1 (sl) 2016-07-29
PT2459592T (pt) 2016-08-17
ME02484B (me) 2017-02-20
CR20120086A (es) 2012-06-01
RS55054B1 (sr) 2016-12-30
US8987420B2 (en) 2015-03-24
IL217680A (en) 2016-04-21
CN104258390A (zh) 2015-01-07
AR077333A1 (es) 2011-08-17
US20150152177A1 (en) 2015-06-04
KR20120087891A (ko) 2012-08-07
AU2010276544B2 (en) 2014-03-27
CA2769334C (en) 2018-06-12
ES2582405T3 (es) 2016-09-12
CO6491118A2 (es) 2012-07-31
US9938339B2 (en) 2018-04-10
CA2769334A1 (en) 2011-02-03
TW201116296A (en) 2011-05-16
RU2545399C2 (ru) 2015-03-27

Similar Documents

Publication Publication Date Title
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
MY165273A (en) Anti-cd48 antibodies and uses thereof
UA104626C2 (ru) Анти-vegf антитело и его применение
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
SG178976A1 (en) High affinity human antibodies to human protease-activated receptor-2
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
PH12012501308A1 (en) Binding members for human cytomegalovirus
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
PH12012502215A1 (en) Anti-fgfr2 antibodies
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF